Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.


TSX:CPH - Post by User

User Avatar Image
(5)
•••
  • PitchinPenniesX
Post by PitchinPennieson Mar 18, 2022 10:25am
413 Views
Post# 34525081

Impressed

ImpressedRetaining the equivalent of a buck in cash for each share is a slick trick, no matter how it was achieved. I'm on record here as bleating that Craig Mull doesn't know what he's doing, but I'd be well beyond happy to be proven wrong -- which might be the case after a few more quarters like this one. Epuris is still in the cross-hairs of competitors. Verity is never anyone's partner of first or even third choice. Cipher still has no presence either in physician offices or on Bay Street. But those are all quibbles. This is a good set of metrics, and I'm well pleased to say so. 
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities